Jefferies Raises Regeneron Price Target to $930

Jefferies Financial Group maintained its Buy rating on Regeneron Pharmaceuticals and raised its price target from $870 to $930, reflecting a positive view of the biotech’s shares. Other analysts’ views were mixed but broadly favorable, leaving the stock with a consensus Moderate Buy rating and an average price target of $809.50. Regeneron also reported quarterly earnings of $14.29 per share, beating analysts’ estimate of $10.16, on revenue of $4.29 billion.